α-Mannosidase 2C1 Attenuates PTEN Function in Prostate Cancer Cells

Overview

Journal Nat Commun

Specialty Biology

Date 2011 May 11

PMID 21556061

Citations 38

Authors

Lizhi He

Catherine Fan

Anil Kapoor

Alistair J Ingram

Adrian P Rybak

Richard C Austin

Jeffery Dickhout

Jean-Claude Cutz

James Scholey

Damu Tang

Affiliations

Soon will be listed here.

Abstract

PTEN dephosphorylates the 3-position phosphate of phosphatidylinositol 3,4,5 triphosphate (PIP(3)), thereby inhibiting AKT activation. Although attenuation of PTEN function has a major role in tumourigenesis, the underlying mechanisms remain unclear. Here we show that α-mannosidase 2C1 (MAN2C1) inhibits PTEN function in prostate cancer (PC) cells and is associated with a reduction in PTEN function in primary PC. MAN2C1 activates AKT and promotes the formation of PTEN-positive DU145 cell-derived xenograft tumours by imparing endogenous PTEN function. In 659 PC patients who were examined, ~60% of tumours were PTEN positive with elevated AKT activation. Of these, 80% display MAN2C1 overexpression that co-localizes with PTEN. Increases in MAN2C1 were detected only in PTEN-positive prostatic intraepithelial neoplasia and carcinomas, and showed a significant association with PC recurrence only in patients with PTEN-positive PCs. Mechanistically, MAN2C1 binds PTEN thereby inhibiting its PIP(3) phosphatase activity. These findings show that MAN2C1 function as a PTEN-negative regulator in PC cells.

Citing Articles

suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase.

Su A, Ding X, Lau H, Kang X, Li Q, Wang X Gut. 2024; 73(9):1478-1488.

PMID: 38599786 PMC: 11347254. DOI: 10.1136/gutjnl-2023-330835.

Synthetic lethal approaches to target cancers with loss of PTEN function.

Ertay A, Ewing R, Wang Y Genes Dis. 2023; 10(6):2511-2527.

PMID: 37533462 PMC: 7614861. DOI: 10.1016/j.gendis.2022.12.015.

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.

Gu Y, Lin X, Dong Y, Wood G, Seidah N, Werstuck G J Exp Clin Cancer Res. 2023; 42(1):2.

PMID: 36588164 PMC: 9806914. DOI: 10.1186/s13046-022-02584-y.

Polympact: exploring functional relations among common human genetic variants.

Valentini S, Gandolfi F, Carolo M, Dalfovo D, Pozza L, Romanel A Nucleic Acids Res. 2022; 50(3):1335-1350.

PMID: 35061909 PMC: 8860573. DOI: 10.1093/nar/gkac024.

Impaired catabolism of free oligosaccharides due to MAN2C1 variants causes a neurodevelopmental disorder.

Maia N, Potelle S, Yildirim H, Duvet S, Akula S, Schulz C Am J Hum Genet. 2022; 109(2):345-360.

PMID: 35045343 PMC: 8874227. DOI: 10.1016/j.ajhg.2021.12.010.

References

Mallory S . Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin. 1995; 13(1):27-31. View

Reddy R, Mao C, Baumeister P, Austin R, Kaufman R, Lee A . Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003; 278(23):20915-24. DOI: 10.1074/jbc.M212328200. View

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

Podsypanina K, Lee R, Politis C, Hennessy I, Crane A, Puc J . An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A. 2001; 98(18):10320-5. PMC: 56959. DOI: 10.1073/pnas.171060098. View

Kim R, Peters M, Jang Y, Shi W, Pintilie M, Fletcher G . DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005; 7(3):263-73. DOI: 10.1016/j.ccr.2005.02.010. View

Lee J, Yang H, Georgescu M, Di Cristofano A, Maehama T, Shi Y . Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999; 99(3):323-34. DOI: 10.1016/s0092-8674(00)81663-3. View

Pelham H . The retention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci. 1990; 15(12):483-6. DOI: 10.1016/0968-0004(90)90303-s. View

Di Cristofano A, Pandolfi P . The multiple roles of PTEN in tumor suppression. Cell. 2000; 100(4):387-90. DOI: 10.1016/s0092-8674(00)80674-1. View

Robertson G, Furnari F, Miele M, Glendening M, Welch D, Fountain J . In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A. 1998; 95(16):9418-23. PMC: 21353. DOI: 10.1073/pnas.95.16.9418. View

10.

Abate-Shen C, Shen M . Molecular genetics of prostate cancer. Genes Dev. 2000; 14(19):2410-34. DOI: 10.1101/gad.819500. View

11.

Hayward S, Dahiya R, Cunha G, Bartek J, Deshpande N, Narayan P . Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim. 1995; 31(1):14-24. DOI: 10.1007/BF02631333. View

12.

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

13.

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

14.

Ao M, Williams K, Bhowmick N, Hayward S . Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 2006; 66(16):8007-16. PMC: 4067141. DOI: 10.1158/0008-5472.CAN-05-4451. View

15.

Shalev N, Wong M, Mills G, Yount G, Stokoe D . Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998; 8(21):1195-8. DOI: 10.1016/s0960-9822(07)00493-9. View

16.

Guha M, Plescia J, Leav I, Li J, Languino L, Altieri D . Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 2009; 69(12):4954-8. PMC: 2718425. DOI: 10.1158/0008-5472.CAN-09-0584. View

17.

Shen M, Abate-Shen C . Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 2007; 67(14):6535-8. DOI: 10.1158/0008-5472.CAN-07-1271. View

18.

Bastola D, Pahwa G, Lin M, Cheng P . Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol Cell Biochem. 2002; 236(1-2):75-81. DOI: 10.1023/a:1016191913274. View

19.

Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J . Genetic background controls tumor development in PTEN-deficient mice. Cancer Res. 2006; 66(13):6492-6. DOI: 10.1158/0008-5472.CAN-05-4143. View

20.

Georgescu M, Kirsch K, Akagi T, Shishido T, Hanafusa H . The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999; 96(18):10182-7. PMC: 17863. DOI: 10.1073/pnas.96.18.10182. View